{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:35:23Z","timestamp":1790804123740,"version":"4.1.0"},"reference-count":37,"publisher":"Wiley","issue":"s2","license":[{"start":{"date-parts":[[2002,11,23]],"date-time":"2002-11-23T00:00:00Z","timestamp":1038009600000},"content-version":"vor","delay-in-days":267,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2002,3]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> Alloantibodies (inhibitors) against factor VIII (FVIII) develop in 20\u201330% of patients with severe haemophilia A and render classical FVIII substitution therapy ineffective. Several studies have shown that genetic factors, the type of FVIII gene mutation and immune response genes (e.g. the Major Histocompatibility Complexes), influence the risk of inhibitor formation. In particular, the type of FVIII gene mutation has proven to be a decisive risk factor. Patients with severe molecular gene defects (e.g. large deletions, nonsense mutations, intron\u201022 inversion) and no endogenous FVIII synthesis have a 7\u201310 times higher inhibitor prevalence than patients with milder molecular gene defects (e.g. missense mutations, small deletions, splice site mutations). To date, at least 10 distinct classes of mutations have been shown which have differing risks of associated inhibitor formation. A challenging observation in inhibitor patients is the heterogeneity of the antibody epitopes with respect to their number and their specifity. At least five epitopes in the FVIII molecule have been identified that constitute the targets for antibodies in most inhibitor patients. These epitopes are located in the ar3 region and the A2, A3, C1, C2 domains which correspond to the functional binding sites of the ligands of the FVIII protein. At present, the determinants of the characteristics of these epitopes and the subsequent inhibitor titre are unknown. A relationship of the mutation site and the epitope localization has been shown for some individual patients with mild haemophilia A. However, in severely affected haemophilia A patients, the influence of patient genetics on inhibitor titre and epitope specifity has yet to be elucidated.<\/jats:p>","DOI":"10.1046\/j.1351-8216.2001.00134.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T23:08:54Z","timestamp":1047424134000},"page":"23-29","source":"Crossref","is-referenced-by-count":132,"title":["Inhibitor development in correlation to factor VIII genotypes"],"prefix":"10.1111","volume":"8","author":[{"given":"J.","family":"Oldenburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"El\u2010Maarri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Schwaab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,11,23]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1000659"},{"key":"e_1_2_4_3_2","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/00001721-199310000-00012","article-title":"Incidence of inhibitors in haemophiliacs. A review of the literature","volume":"4","author":"Scharrer I","year":"1993","journal-title":"Blood Coag Fibrinolysis"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1649954"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1655945"},{"key":"e_1_2_4_6_2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1055\/s-0038-1655944","article-title":"HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party","volume":"77","author":"Hay CR","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.1089\/10430349950017095"},{"key":"e_1_2_4_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/26.1.216"},{"key":"e_1_2_4_9_2","first-page":"7","article-title":"Risk factors for inhibitor development in haemophilia A","volume":"85","author":"Oldenburg J","year":"2000","journal-title":"Haematologica"},{"key":"e_1_2_4_10_2","first-page":"565","article-title":"Partial correction of a severe molecular defect in haemophilia A, because of errors during expression of the factor VIII gene","volume":"60","author":"Young M","year":"1997","journal-title":"Am J Hum Genet"},{"key":"e_1_2_4_11_2","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1055\/s-0037-1615015","article-title":"Small deletion\/ insertion mutations within poly\u2010A\u2010runs of the factor VIII gene mitigate the severe haemophilia A phenotype","volume":"79","author":"Oldenburg J","year":"1998","journal-title":"Thromb Haemost"},{"key":"e_1_2_4_12_2","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1055\/s-0038-1656068","article-title":"Factor VIII Ise (R2159 C) in a patient with mild haemophilia A, an abnormal factor VIII with retention of function but modification of C2 epitopes","volume":"77","author":"Suzuki H","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_4_13_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615061"},{"key":"e_1_2_4_14_2","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1182\/blood.V96.3.958","article-title":"A novel cause of mild\/moderate haemophilia A. mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor","volume":"96","author":"Jacquemin M","year":"2000","journal-title":"Blood"},{"key":"e_1_2_4_15_2","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1182\/blood.V96.3.979","article-title":"Haemophilic factor VIII C1\u2010 and C2\u2010domain missense mutations and their modeling to the 1.5\u2010angstrom human C2\u2010domain crystal structure","volume":"96","author":"Liu ML","year":"2000","journal-title":"Blood"},{"issue":"2","key":"e_1_2_4_16_2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/46601","article-title":"Structure of the C2 domain of human factor VIII at 1.5 A resolution","volume":"402","author":"Pratt KP","year":"1999","journal-title":"Nature"},{"key":"e_1_2_4_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00300.x"},{"key":"e_1_2_4_18_2","first-page":"162","article-title":"Recombinant FVIII (Kogenate) treatment of previously untreated patients (PUPs) with haemophilia A. Update of safety, efficacy and inhibitor development after seven study years. ISTH Florence","author":"Lusher J","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_4_19_2","first-page":"228","article-title":"Safety and immunogenicity of recombinant factor VIII (Recombinate) in previously untreated patients (PUPs). A 7.3 year update. WFH The Hague","volume":"4","author":"Gruppo R","year":"1998","journal-title":"Haemophilia"},{"key":"e_1_2_4_20_2","first-page":"239","article-title":"Increased frequency of inhibitors in African American haemophilia A patients. ASH Nashville","author":"Addiego J","year":"1994","journal-title":"Blood"},{"key":"e_1_2_4_21_2","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1055\/s-0037-1615871","article-title":"The role of Genetics in Inhibitor Formation","volume":"82","author":"Cox Gill J.","year":"1999","journal-title":"Thromb Haemost"},{"key":"e_1_2_4_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb07878.x"},{"key":"e_1_2_4_23_2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1055\/s-0038-1653453","article-title":"HLA antigens and factor VIII antibody in classic haemophilia. European study group of factor VIII antibody","volume":"46","author":"Frommel D","year":"1981","journal-title":"Thromb Haemost"},{"key":"e_1_2_4_24_2","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1055\/s-0038-1647359","article-title":"Relationship of major histocompatibility complex class II genes to inhibitor antibody formation in haemophilia A","volume":"64","author":"Lippert LE","year":"1990","journal-title":"Thromb Haemost"},{"key":"e_1_2_4_25_2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1055\/s-0038-1661081","article-title":"antibodies in haemophilia A","volume":"51","author":"Mayr WR","year":"1984","journal-title":"Thromb Haemost"},{"key":"e_1_2_4_26_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.178.1.27"},{"key":"e_1_2_4_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-199003000-00003"},{"key":"e_1_2_4_28_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.24.14505"},{"key":"e_1_2_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(92)90161-3"},{"key":"e_1_2_4_30_2","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1182\/blood.V95.2.564","article-title":"Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply\u2010substituted hybrid human\/porcine factor VIII molecules","volume":"95","author":"Barrow RT","year":"2000","journal-title":"Blood"},{"key":"e_1_2_4_31_2","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.V91.7.2347","article-title":"A human alloantibody interferes with binding of factor IXa to the factor VIII light chain","volume":"91","author":"Fijnvandraat K","year":"1998","journal-title":"Blood"},{"key":"e_1_2_4_32_2","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1182\/blood.V92.10.3701","article-title":"Residues Glu2181\u2010Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII","volume":"92","author":"Healey JF","year":"1998","journal-title":"Blood"},{"key":"e_1_2_4_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.5.1811.bloodjournal8651811"},{"key":"e_1_2_4_34_2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood.V95.1.156","article-title":"A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor","volume":"95","author":"Jacquemin M","year":"2000","journal-title":"Blood"},{"key":"e_1_2_4_35_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.11.3983"},{"key":"e_1_2_4_36_2","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1182\/blood.V74.5.1618.1618","article-title":"Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization","volume":"74","author":"Scandella D","year":"1989","journal-title":"Blood"},{"key":"e_1_2_4_37_2","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1182\/blood.V93.7.2267","article-title":"Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild haemophilia A","volume":"93","author":"Peerlinck K","year":"1999","journal-title":"Blood"},{"key":"e_1_2_4_38_2","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1182\/blood.V89.12.4371","article-title":"The missense mutation Arg593 \u2192 Cys is related to antibody formation in a patient with mild haemophilia A","volume":"89","author":"Fijnvandraat K","year":"1997","journal-title":"Blood"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1351-8216.2001.00134.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1351-8216.2001.00134.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T16:14:47Z","timestamp":1695744887000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1351-8216.2001.00134.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3]]},"references-count":37,"journal-issue":{"issue":"s2","published-print":{"date-parts":[[2002,3]]}},"alternative-id":["10.1046\/j.1351-8216.2001.00134.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1351-8216.2001.00134.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,3]]}}}